Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David E Cohn

Showing results (211-220 of 302) with videos related to

Pageof 31
Sort By:
American Journal of Obstetrics and Gynecology|December 27, 2022
Postoperative venous thromboembolism risk stratification in patients with uterine cancerVincent M Wagner, Rachael N Piver, Monica D Levine, et al.
Cancer Research|January 18, 2018
<i>STAT3/PIAS3</i> Levels Serve as "Early Signature" Genes in the Development of High-Grade Serous Carcinoma from the Fallopian TubeUksha Saini, Adrian A Suarez, Shan Naidu, et al.
Gynecologic Oncology Reports|March 13, 2023
Use of the Khorana score to predict venous thromboembolism in patients undergoing chemotherapy for uterine cancerRachael N Piver, Vincent M Wagner, Monica D Levine, et al.
Translational Research : the Journal of Laboratory and Clinical Medicine|October 16, 2012
Assessment of FANCD2 nuclear foci formation in paraffin-embedded tumors: a potential patient-enrichment strategy for treatment with DNA interstrand crosslinking agentsWenrui Duan, Li Gao, Weiqiang Zhao, et al.
Gynecologic Oncology|December 25, 2012
Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group studyEdwin A Alvarez, William E Brady, Joan L Walker, et al.
Oncogene|June 14, 2016
Elevated STAT3 expression in ovarian cancer ascites promotes invasion and metastasis: a potential therapeutic targetUksha Saini, Shan Naidu, Adam C ElNaggar, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|June 13, 2015
Evaluation of the Hematologic Safety of Same Day Versus Standard Administration (24- to 72-Hour Delay) of Pegfilgrastim in Gynecology Oncology Patients Undergoing Cytotoxic ChemotherapyCaroline C Billingsley, Samuel N Jacobson, Sarah M Crafton, et al.
Gynecologic Oncology|March 15, 2013
Etiologic heterogeneity in endometrial cancer: evidence from a Gynecologic Oncology Group trialLouise A Brinton, Ashley S Felix, D Scott McMeekin, et al.
Gynecologic Oncology|October 12, 2016
Does time interval between surgery and intraperitoneal chemotherapy administration in advanced ovarian cancer carry a prognostic impact? An NRG Oncology/Gynecologic Oncology Group study ancillary studyArlene E Garcia-Soto, James J Java, Wilberto Nieves Neira, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 8, 2014
Phase III randomized trial of weekly cisplatin and irradiation versus cisplatin and tirapazamine and irradiation in stages IB2, IIA, IIB, IIIB, and IVA cervical carcinoma limited to the pelvis: a Gynecologic Oncology Group studyPaul A DiSilvestro, Shamshad Ali, Peter S Craighead, et al.
Pageof 31

Showing results (211-220 of 302) with videos related to

Sort By:
Pageof 31
American Journal of Obstetrics and Gynecology|December 27, 2022
Postoperative venous thromboembolism risk stratification in patients with uterine cancerVincent M Wagner, Rachael N Piver, Monica D Levine, et al.
Cancer Research|January 18, 2018
<i>STAT3/PIAS3</i> Levels Serve as "Early Signature" Genes in the Development of High-Grade Serous Carcinoma from the Fallopian TubeUksha Saini, Adrian A Suarez, Shan Naidu, et al.
Gynecologic Oncology Reports|March 13, 2023
Use of the Khorana score to predict venous thromboembolism in patients undergoing chemotherapy for uterine cancerRachael N Piver, Vincent M Wagner, Monica D Levine, et al.
Translational Research : the Journal of Laboratory and Clinical Medicine|October 16, 2012
Assessment of FANCD2 nuclear foci formation in paraffin-embedded tumors: a potential patient-enrichment strategy for treatment with DNA interstrand crosslinking agentsWenrui Duan, Li Gao, Weiqiang Zhao, et al.
Gynecologic Oncology|December 25, 2012
Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group studyEdwin A Alvarez, William E Brady, Joan L Walker, et al.
Oncogene|June 14, 2016
Elevated STAT3 expression in ovarian cancer ascites promotes invasion and metastasis: a potential therapeutic targetUksha Saini, Shan Naidu, Adam C ElNaggar, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|June 13, 2015
Evaluation of the Hematologic Safety of Same Day Versus Standard Administration (24- to 72-Hour Delay) of Pegfilgrastim in Gynecology Oncology Patients Undergoing Cytotoxic ChemotherapyCaroline C Billingsley, Samuel N Jacobson, Sarah M Crafton, et al.
Gynecologic Oncology|March 15, 2013
Etiologic heterogeneity in endometrial cancer: evidence from a Gynecologic Oncology Group trialLouise A Brinton, Ashley S Felix, D Scott McMeekin, et al.
Gynecologic Oncology|October 12, 2016
Does time interval between surgery and intraperitoneal chemotherapy administration in advanced ovarian cancer carry a prognostic impact? An NRG Oncology/Gynecologic Oncology Group study ancillary studyArlene E Garcia-Soto, James J Java, Wilberto Nieves Neira, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 8, 2014
Phase III randomized trial of weekly cisplatin and irradiation versus cisplatin and tirapazamine and irradiation in stages IB2, IIA, IIB, IIIB, and IVA cervical carcinoma limited to the pelvis: a Gynecologic Oncology Group studyPaul A DiSilvestro, Shamshad Ali, Peter S Craighead, et al.
Pageof 31